Advanced Pancreatic Ductal Adenocarcinoma (PDAC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive lethal malignancy due to the lack of early diagnosis and limited response to treatments. It is the most prevalent type of pancreatic neoplasm, and it is developed in the exocrine compartment and accounts for more than 90% of pancreatic cancer cases. Advanced pancreatic ductal adenocarcinoma (PDAC) remains a significant cause of mortality, accounting for up to 4% of all cancer-related deaths worldwide. Of concern, despite treatment, the mortality rates have remained high and unchanged over the last two decades. Furthermore, even in the setting of adjuvant therapy, 5-year survival rates remain poor at only 25%, while for metastatic disease, it is 1%. As a consequence, there is an ongoing need for the development of improved diagnostic techniques, treatment options and surveillance markers to improve the outcomes for this devastating disease. Pancreaticoduodenectomy is the most common surgery for pancreatic head carcinomas.
·
The incidence of PDAC is increasing at a rate
of 0.5% to 1.0% per year, and it is expected to be the second leading cause of
cancer-related mortality by 2030.
Thelansis’s
“Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Market Outlook, Epidemiology,
Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers
disease overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Advanced
Pancreatic Ductal Adenocarcinoma (PDAC) treatment modalities options for eight
major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Advanced Pancreatic
Ductal Adenocarcinoma (PDAC) across 8 MM market from the centre of Excellence/
Public/ Private hospitals participated in the study. Insights around current
treatment landscape, epidemiology, clinical characteristics, future treatment
paradigm, and Unmet needs.
Advanced
Pancreatic Ductal Adenocarcinoma (PDAC) Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment